40 nesposobnosti za rad radno aktivnog stanovništva. Stoga, dobra regulacija šederne bolesti te održavanje normoglikemije u krvi je najvažniji način prevencije razvoja komplikacija dijabetesa. Dijabetička makulopatija je komplikacija bolesti koju je, ne tako davno, bilo vrlo teško liječiti, a pogotovo vratiti izgubljeni vid bolesniku. Sve do nedavno laser fotokoagulacija bila je jedina i osnovna metoda liječenja dijabetičke retinopatije i makulopatije čiji je cilj liječenja prevencija daljnjeg pogoršanja vidne oštrine. S obzirom da CI-DME predstavlja veliku opasnost od gubitka vida, a laserom se ne postižu zadovoljavajudi rezultati u rješavanju CI-DME, počelo se pribjegavati farmakološkim metodama liječenja makulopatije. Danas postoje blokatori angiogeneze za intravitrealnu primjenu koji predstavljaju prvi izbor u liječenju dijabetičke makulopatije, ali i drugih vaskularnih bolesti retine. Ključne riječi: dijabetički makularni edem, anti - VEGF lijekovi, liječenje 9. SUMMARY Diabetes mellitus is a chronic disease that places a significant burden on public health care systems around the world. The complications due to diabetes at one point become irreversible, leading to diminishing people's life quality and inability to work in working - age adults. Therefore, maintaining normal blood sugar level is crucial for preventing complications of diabetes. Until recently, the treatment for diabetic maculopathy was very limited and it was almost impossible to recuperate the patient's vision loss. Laser photocoagulation was the only available method for treating diabetic 41 retinopathy and maculopathy for the last 40 years. Because of poor resultes obtained by laser treatment in patients with central involved - diabetic macular edema (CI-DME), all the efforts have been directed towards developing new pharmacological agents in order to provide more effective tretment for DME. Currently there is a number of therapeutic options for the treatment of visual impairment due to DME. More recently, the most popular drugs for treating DME are intravitreal anti - VEGF agents. Anti – VEGF therapy has revolutionized DME treatment because those drugs do not only stabilize, but also restore vision in a substantial proportion of those treated.